Latest CanVECTOR News
 

Annual incidence of

2/1000

population per year

Cost of VTE: at least

$600m

CAD a year

VTE recurrence

5-10%

per year

Chronic thromboembolic pulmonary hypertension 

3-4%

after PE

Pulmonary Embolism
leads to the hospitalization
or death of over

30,000

Canadians every year

VTE leads to significant

long-term
costs

in the form of chronic complications of VTE

Post-thrombotic syndrome

20-40%

after DVT

Adverse effects and

burden of anticoagulant therapy

Upcoming Events

Evidence Pearls on VTE

Evidence Pearls on VTE RSS Feed
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation.
Mar 29, 2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Mar 29, 2017
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Mar 29, 2017
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Mar 29, 2017
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation.
Mar 28, 2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Mar 28, 2017
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Mar 28, 2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Mar 27, 2017
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Mar 27, 2017
Risk of Pulmonary Embolism After Cerebral Venous Thrombosis.
Mar 27, 2017
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation.
Mar 27, 2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Mar 26, 2017
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Mar 26, 2017
Risk of Pulmonary Embolism After Cerebral Venous Thrombosis.
Mar 26, 2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Mar 25, 2017
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Mar 25, 2017
Risk of Pulmonary Embolism After Cerebral Venous Thrombosis.
Mar 25, 2017
Risk of Pulmonary Embolism After Cerebral Venous Thrombosis.
Mar 24, 2017
The original and simplified Wells rules and age-adjusted D-dimer testing to rule out pulmonary embolism: an individual patient data meta-analysis.
Mar 24, 2017
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study.
Mar 24, 2017

Twitter